Immuno-Oncology | Specialty

Expert Discusses Next Steps for Durvalumab in Bladder Cancer

August 23rd 2017

Peter Black, MD, discusses the latest on durvalumab and other ongoing developments in the field of bladder cancer.

Andtbacka Discusses Long-Term Data and Next Steps With T-VEC in Melanoma

August 22nd 2017

Robert Andtbacka, MD, discusses the long-term results for T-VEC in melanoma and the remaining challenges with the oncolytic immunotherapy.

Dr. Martin on Potential of Immunotherapy in MCL Landscape

August 18th 2017

Peter Martin, MD, assistant professor of medicine in the Division of Hematology/Oncology at Weill Cornell Medical College, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the potential of modern immunotherapies in the landscape of mantle cell lymphoma (MCL).

Drake Discusses Immunomodulatory Therapies

August 18th 2017

Charles Drake, MD, PhD, shares his insight on the promise and challenges with immunomodulatory drugs, and immune-activating agents in prostate cancer.

Dr. Sartor on the Science of Sipuleucel-T for Prostate Cancer

August 18th 2017

Oliver Sartor, MD, a medical oncologist at the Tulane University School of Medicine, discusses the science behind the results of a study investigating sipuleucel-T (Provenge) for patients with castration-resistant prostate cancer (CRPC).

Expert Explains Approaches in Non-Driver NSCLC

August 18th 2017

Lyudmila A. Bazhenova, MD, discusses the non-driver NSCLC population, the treatment strategies available for them, and challenges physicians continue to face with this subgroup of patients.

Dr. Ornstein on Challenges With Immunotherapy in RCC

August 17th 2017

Moshe Ornstein, MD, staff, Cleveland Clinic, discusses the challenges surrounding immunotherapy for patients with renal cell carcinoma.

Dr. Slovin on Approaches of Immunotherapy in Prostate Cancer

August 17th 2017

Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses approaches of immunotherapy for patients with prostate cancer.

Frontline Nivolumab/Ipilimumab Improves Response in mRCC

August 16th 2017

The combination of nivolumab (Opdivo) and ipilimumab (Yervoy) improved the objective response rate and duration of response compared with sunitinib (Sutent) in patients with treatment-naïve metastatic renal cell carcinoma, according to CheckMate-214.

Dr. Atkins Discusses Response to Atezolizumab in RCC

August 16th 2017

Michael B. Atkins, MD, deputy director, Georgetown-Lombardi Comprehensive Cancer Center, professor of oncology and medicine, Georgetown University School of Medicine, discusses responses with atezolizumab (Tecentriq) in renal cell carcinoma.

ASCO Updates Treatment Guidelines for Advanced NSCLC

August 16th 2017

ASCO has updated its guidelines for first- and second-line treatment of patients with stage IV non–small cell lung cancer.

IDO Inhibitors Emerging as New Players on Checkpoint Blockade Scene

August 15th 2017

As researchers continue to explore immune checkpoints as targets for anticancer therapies, the IDO pathway has emerged as the leading contender to yield the next batch of new drugs in the field.

Dr. Plimack on the Challenges With Available Immunotherapies for Bladder Cancer

August 15th 2017

Elizabeth Plimack, MD, director of Genitourinary Clinical Research at Fox Chase Cancer Center, shares the challenges with the FDA-approved immunotherapy agents for the treatment of patients with bladder cancer.

Dr. Vokes on Pembrolizumab Plus Chemotherapy and Radiation in Lung Cancer

August 15th 2017

Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, chair, Department of Medicine, University of Chicago Medicine, discusses pembrolizumab (Keytruda) plus chemotherapy and radiation therapy in patients with lung cancer.

RT Options Evolving in Oligometastatic Lung Cancer Landscape and Beyond

August 14th 2017

Billy W. Loo Jr, MD, PhD, discusses the advancements in radiation therapy options for patients with lung cancer, how SABR has improved outcomes for patients, and the intriguing combinations being explored with RT and immunotherapy.

Frontline Pembrolizumab Explored in Head and Neck Cancer

August 11th 2017

Jean-Pascal Machiels, MD, discusses the KEYNOTE-412 trial and the overall potential for pembrolizumab in the head and neck cancer landscape.

Dr. Hammers on the Future of Treatments for RCC

August 11th 2017

Hans J. Hammers, MD, PhD, associate professor, Internal Medicine, UT Southwestern Medical Center, discusses the future of treatments for patients with renal cell carcinoma (RCC).

Dr. Black on Biomarkers for Immunotherapy in Bladder Cancer

August 10th 2017

Peter Black, MD, senior research scientist, Vancouver Prostate Centre, associate professor, Department of Urologic Sciences, University of British Columbia, discusses biomarker development in bladder cancer.

Dr. Sartor on the Next Steps with Sipuleucel-T for Prostate Cancer

August 10th 2017

Oliver Sartor, MD, a medical oncologist at the Tulane University School of Medicine, discusses the next steps with sipuleucel-T (Provenge) for patients with prostate cancer.

Dr. Weiss on Developments in the Treatment of Head and Neck Cancer

August 10th 2017

Jared Weiss, MD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses developments of immunotherapy trials for patients with head and neck cancer.